<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548482" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548482/" /><meta name="ncbi_pagename" content="Rilonacept - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Rilonacept - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Rilonacept" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/04/20" /><meta name="citation_pmid" content="31643801" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548482/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Rilonacept" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/04/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548482/" /><meta name="description" content="Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes (CAPS) and other autoinflammatory conditions. Rilonacept has had limited clinical use and has yet to be linked to cases of clinically apparent, acute liver injury." /><meta name="og:title" content="Rilonacept" /><meta name="og:type" content="book" /><meta name="og:description" content="Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes (CAPS) and other autoinflammatory conditions. Rilonacept has had limited clinical use and has yet to be linked to cases of clinically apparent, acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548482/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Rilonacept/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548482/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE890404046692E10000000008BC027D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548482_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548482_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Rifaximin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Rilpivirine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548482_"><span class="title" itemprop="name">Rilonacept</span></h1><p class="small">Last Update: <span itemprop="dateModified">April 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Rilonacept.OVERVIEW"><h2 id="_Rilonacept_OVERVIEW_">OVERVIEW</h2><div id="Rilonacept.Introduction"><h3>Introduction</h3><p>Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes (CAPS) and other autoinflammatory conditions. Rilonacept has had limited clinical use and has yet to be linked to cases of clinically apparent, acute liver injury.</p></div><div id="Rilonacept.Background"><h3>Background</h3><p>Rilonacept (ril on&#x02019; a sept) is a recombinant fusion protein which includes the extracellular portion of the human IL-1 receptor and the IL-1 receptor accessory protein fused with the Fc portion of human IgG1. Rilonacept binds and inactivates IL-1, acting as an &#x0201c;IL-1 trap&#x0201d;. IL-1 is a key proinflammatory cytokine that is a powerful inducer of fever and inflammation. Excessive production of IL-1 or lack of its inactivation is believed to play a major role in many autoinflammatory conditions and particularly in cold induced autoinflammatory conditions such as cryopyrin associated periodic syndromes (CAPS). IL-1 may also play an important role in inflammatory arthritides and familial Mediterranean fever. In controlled trials and open label studies, rilonacept has been shown to improve symptoms and laboratory abnormalities associated CAPS and, to a lesser extent, in patients with gouty arthritis, juvenile idiopathic arthritis, familial Mediterranean fever and in rare forms of autoinflammatory conditions such as Schnitzler syndrome. Rilonacept was approved for use in the United States in 2010 to treat CAPS. Rilonacept is given by subcutaneous injection in a loading dose of 320 mg and a maintenance dose of 160 mg weekly. Rilonacept is available in vials of 20 mL containing 222 mg of rilonacept under the brand name Arcalyst. The most frequent side effects are injection site reactions, upper respiratory symptoms, headache, nausea and hypertension. Potential serious adverse events include life-threatening infections and hypersensitivity reactions</p></div><div id="Rilonacept.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In clinical trials, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations were rarely mentioned as an adverse event in patients receiving rilonacept, but minor overall increases in both ALT and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels were described (1-4%). The timing, severity and outcome of these elevations were not characterized, but there were no instances of jaundice or clinically apparent liver injury. Most ALT elevations were without symptoms or elevations in bilirubin or alkaline phosphatase and no long term hepatic effects were observed. Patients with autoinflammatory conditions such as CAPS frequently have mild-to-moderate elevations in serum enzymes and typically these improve with treatment using inhibitors of IL-1 signaling. Since its approval, there have been no published reports of hepatotoxicity due to rilonacept, although its use has been limited. In addition, rilonacept has not been linked to cases of reactivation of hepatitis B or exacerbation of chronic hepatitis C which can occur with other cytokines and anticytokines.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Rilonacept.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Rilonacept is a recombinant protein and has little hepatic metabolism. Any liver injury due to rilonacept is more likely due to its effect on the immune system or on IL-1 pathways rather than a direct toxic effect on the liver.</p></div><div id="Rilonacept.Outcome_and_Management"><h3>Outcome and Management</h3><p>Agents that block the proinflammatory pathways of IL-1 and IL-6 share similar activity against autoinflammatory diseases and have little evidence for serious hepatotoxicity. There is no reason to suspect that there may be cross sensitivity to hepatic injury between rilonacept and other immune modulating biologic agents or anti-IL1 blockers such as anakinra, canakinumab and tocilizumab.</p><p>Drug Class: <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/InterleukinRcptAntag/">Interleukin Receptor Antagonists</a>: <a href="/books/n/livertox/Anakinra/">Anakinra</a>, <a href="/books/n/livertox/Canakinumab/">Canakinumab</a>, <a href="/books/n/livertox/Sarilumab/">Sarilumab</a>, <a href="/books/n/livertox/Tocilizumab/">Tocilizumab</a></p></div></div><div id="Rilonacept.PRODUCT_INFORMATION"><h2 id="_Rilonacept_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Rilonacept &#x02013; Arcalyst&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antirheumatic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=rilonacept" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Rilonacept.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Rilonacept_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Rilonacept.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548482/table/Rilonacept.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rilonacept.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Rilonacept.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Rilonacept.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Rilonacept.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Rilonacept.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Rilonacept.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rilonacept</td><td headers="hd_h_Rilonacept.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">501081-76-1</td><td headers="hd_h_Rilonacept.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C9030-<a href="/nuccore/878752" class="bk_tag" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=nuccore">H13932</a>-N2400-O2670-S74</td><td headers="hd_h_Rilonacept.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No Structure</td></tr></tbody></table></div></div></div><div id="Rilonacept.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Rilonacept_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 April 2020</p><p>Abbreviations: IL-1, interleukin 1; CAPS, cryopyrin-associated periodic syndrome.</p><p>Abbreviations: IL1, interleukin 1; CAPS, cryopyrin-associated periodic syndrome; DMARD, disease modifying anti-rheumatic drug; TRAPS, tumor necrosis factor receptor associated periodic syndrome.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Rilonacept.REF.zimmerman.1999">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-53.<div><i>(Expert review of hepatotoxicity published in 1999 before the availability of rilonacept and other recombinant proteins and anticytokines).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.goldbachmansky.2008.2432">Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, et al.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. <span><span class="ref-journal">Arthritis Rheum. </span>2008;<span class="ref-vol">58</span>:2432–42.</span> [<a href="/pmc/articles/PMC2875198/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2875198</span></a>] [<a href="/pubmed/18668591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18668591</span></a>]<div><i>(Among 5 patients with familial cold autoinflammatory syndrome treated with rilonacept [100-160 mg weekly], all had a clinical response to therapy and 3 had mild, transient elevations in ALT or AST).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.hoffman.2008.2443">Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, et al.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. <span><span class="ref-journal">Arthritis Rheum. </span>2008;<span class="ref-vol">58</span>:2443–52.</span> [<a href="/pubmed/18668535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18668535</span></a>]<div><i>(Among 47 adults with CAPS enrolled in a controlled trial of rilonacept vs placebo for 6 weeks followed by a 9 weeks of open therapy and then continuation or withdrawal, "small increases in mean ALT and AST levels" were reported with rilonacept, but these changes were not clinically significant).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.church.2009.14">Church LD, McDermott MF. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. <span><span class="ref-journal">Nat Clin Pract Rheumatol. </span>2009;<span class="ref-vol">5</span>:14–5.</span> [<a href="/pubmed/19015646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19015646</span></a>]<div><i>(Commentary on studies of rilonacept in CAPS [Hoffman and Goldbach-Mansky, 2008]; no mention of hepatotoxicity or ALT elevations during treatment).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.furst.2010.327">Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2010;<span class="ref-vol">39</span>:327–46.</span> [<a href="/pubmed/19117595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19117595</span></a>]<div><i>(Review of the excess risk of infections during biologic therapy of rheumatoid arthritis mentions that the rate of infections was 2.1% in anakinra treated patients vs 0.4% in controls; infections were primarily pneumonia and skin infections, none were fatal and few were opportunistic infections).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.carroll.2011.533">Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. <span><span class="ref-journal">Expert Opin Biol Ther. </span>2011;<span class="ref-vol">11</span>:533–44.</span> [<a href="/pubmed/21269234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21269234</span></a>]<div><i>(Review of reactivation of hepatitis B by biologic response modifiers; rilonacept has not been linked to reactivation of HBV, although the experience in treating patients with HBsAg has been limited).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.dubois.2011.639">Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2011;<span class="ref-vol">71</span>:639–41.</span> [<a href="/pmc/articles/PMC3093069/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3093069</span></a>] [<a href="/pubmed/21375570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21375570</span></a>]<div><i>(Short review of mechanism of action, clinical efficacy and safety of rilonacept and canakinumab; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.miyamae.2012.109">Miyamae T. Cryopyrin-associated periodic syndromes: diagnosis and management. <span><span class="ref-journal">Paediatr Drugs. </span>2012;<span class="ref-vol">14</span>:109–17.</span> [<a href="/pubmed/22335455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22335455</span></a>]<div><i>(Review of the clinical features and pathogenesis [mutation in NLRP3 gene] of cryopyrin associated periodic syndromes [CAPS] and currently available treatments including anakinra [recombinant IL-1Ra], rilonacept [recombinant IL-1 trap] and canakinumab [monoclonal antibody to IL-1 beta]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF10">Drugs for rheumatoid arthritis. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2012;<span class="ref-vol">10</span>(117):37–44.</span> [<a href="/pubmed/22538522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22538522</span></a>]<div><i>(Concise summary on current therapies of rheumatoid arthritis discusses anakinra and tocilizumab, but not rilonacept or canakinumab).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.dinarello.2012.633">Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2012;<span class="ref-vol">11</span>:633–52.</span> [<a href="/pmc/articles/PMC3644509/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644509</span></a>] [<a href="/pubmed/22850787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22850787</span></a>]<div><i>(Review of the biologic actions of IL-1 and the clinical efficacy and safety of agents that block its activity including anakinra [IL-1Ra], canakinumab [monoclonal antibody to IL-1 beta] and rilonacept [recombinant soluble IL-1 receptor]).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.hashkes.2012.533">Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, Barron KS, et al.  Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. <span><span class="ref-journal">Ann Intern Med. </span>2012;<span class="ref-vol">157</span>:533–41.</span> [<a href="/pubmed/23070486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23070486</span></a>]<div><i>(Among 14 patients with familial Mediterranean fever treated with sequential 3 month courses of rilonacept or placebo, attacks were less frequent during rilonacept therapy; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.hoffman.2012.2091">Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. <span><span class="ref-journal">Clin Ther. </span>2012;<span class="ref-vol">34</span>:2091–103.</span> [<a href="/pubmed/23031624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23031624</span></a>]<div><i>(Analysis of long term efficacy and safety of rilonacept in 101 patients with CAPS treated in an open label study for up to 2 years; mean levels of ALT and AST rose in patients receiving rilonacept [2-4 U/L], and therapy was temporarily discontinued in 2 patients because of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.krause.2012.943">Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, Zuberbier T, Maurer M. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. <span><span class="ref-journal">Allergy. </span>2012;<span class="ref-vol">67</span>:943–50.</span> [<a href="/pubmed/22583335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22583335</span></a>]<div><i>(Among 8 patients with Schnitzler syndrome treated with rilonacept for up to 1 year, symptoms and inflammatory markers improved and there were "no significant changes in safety laboratory values").</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.petryna.2012.2056">Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. <span><span class="ref-journal">Ann Rheum Dis. </span>2012;<span class="ref-vol">71</span>:2056–7.</span> [<a href="/pubmed/22679302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22679302</span></a>]<div><i>(Among 3 patients with refractory adult-onset Still disease treated with weekly injections of rilonacept, all had a complete remission maintained for 16-28 months and were able to reduce or stop corticosteroids; no adverse events reported).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.lovell.2013.2486">Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, Wallace CA, et al.  Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). <span><span class="ref-journal">Arthritis Rheum. </span>2013;<span class="ref-vol">65</span>:2486–96.</span> [<a href="/pubmed/23754188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23754188</span></a>]<div><i>(Among 24 children with juvenile idiopathic arthritis treated with rilonacept for up to 2 years, the most common adverse event was injection site reactions; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.mitha.2013.1285">Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, Wang J, et al.  Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. <span><span class="ref-journal">Rheumatology (Oxford). </span>2013;<span class="ref-vol">52</span>:1285–92.</span> [<a href="/pubmed/23485476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23485476</span></a>]<div><i>(Among 248 patients with acute gouty arthritis treated with 2 doses of rilonacept or placebo once weekly for 16 weeks, acute flares were reduced with rilonacept therapy, but adverse events were similar in the two groups except for injection site reactions; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.terkeltaub.2013.r25">Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. <span><span class="ref-journal">Arthritis Res Ther. </span>2013;<span class="ref-vol">15</span>:R25.</span> [<a href="/pmc/articles/PMC3672764/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3672764</span></a>] [<a href="/pubmed/23375025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23375025</span></a>]<div><i>(Among 225 patients with acute gouty arthritis treated with rilonacept versus indomethacin vs the combination, there were no differences in pain scores with addition of rilonacept; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.ilowite.2014.2570">Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, Verbsky JW, et al.  Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. <span><span class="ref-journal">Arthritis Rheumatol. </span>2014;<span class="ref-vol">66</span>:2570–9.</span> [<a href="/pmc/articles/PMC4314719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4314719</span></a>] [<a href="/pubmed/24839206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24839206</span></a>]<div><i>(Among 50 children with juvenile idiopathic arthritis treated with rilonacept or placebo for 4 weeks and then with open label rilonacept for up to 24 weeks, response rates were higher with rilonacept, and 4 patients receiving rilonacept developed elevated ALT levels that were above 5 times ULN in 2 [4%]).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.sundy.2014.1703">Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, Evans RR. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. <span><span class="ref-journal">J Rheumatol. </span>2014;<span class="ref-vol">41</span>:1703–11.</span> [<a href="/pubmed/25028379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25028379</span></a>]<div><i>(Among 1315 adults with gout treated with rilonacept or placebo for 16 weeks, rilonacept was associated with fewer gout flares but higher rates of ALT elevations [1.1% vs 0.6%]).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to rilonacept or other IL-1 antagonists).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.winthrop.2018.s21">Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, et al.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). <span><span class="ref-journal">Clin Microbiol Infect. </span>2018;<span class="ref-vol">24</span> Suppl 2:S21–S40.</span> [<a href="/pubmed/29447987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29447987</span></a>]<div><i>(Review of the risk of infections in patients receiving biologic therapies targeting interleukins and immunoglobulins concludes that patients taking IL-1 targeted agents have a moderate increased risk for infections, should be prescreened for tuberculosis and monitored for infections during therapy).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.garg.2017.94838">Garg M, de Jesus AA, Chapelle D, Dancey P, Herzog R, Rivas-Chacon R, Muskardin TLW, et al.  Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. <span><span class="ref-journal">JCI Insight. </span>2017;<span class="ref-vol">2</span>:94838. </span> pii. [<a href="/pmc/articles/PMC5621891/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5621891</span></a>] [<a href="/pubmed/28814674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28814674</span></a>]<div><i>(6 children with IL-1r antagonist deficiency receiving daily injections of anakinra for 3 to 6 years were switched to once-weekly rilonacept and all had complete remissions with improved quality of life; adverse events included upper respiratory infections and gastrointestinal symptoms but no patient discontinued therapy; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.mantero.2018.146">Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, et al.  Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. <span><span class="ref-journal">Clin Exp Rheumatol. </span>2018;<span class="ref-vol">36</span> Suppl 113:146–9.</span> [<a href="/pubmed/30277862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30277862</span></a>]<div><i>(Among 19 patients with systemic sclerosis treated with 6 weekly injections or rilonacept or placebo, symptoms and markers of disease activity did not change with therapy while adverse events included injection site reactions).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.giacomelli.2018.24">Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. <span><span class="ref-journal">J Autoimmun. </span>2018;<span class="ref-vol">93</span>:24–36.</span> [<a href="/pubmed/30077425" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30077425</span></a>]<div><i>(Review of the pathogenesis, clinical features, complications and therapy of adult onset Still&#x02019;s disease mentions that liver test abnormalities have been reported in 37-74% of subjects and that anakinra has been studied in at least 13 small open label trials with response rates of 46-100%, and both canakinumab or rilonacept have been found to be helpful in cases with intolerance or an inadequate response to anakinra).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.crayne.2019.119">Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of macrophage activation syndrome. <span><span class="ref-journal">Front Immunol. </span>2019;<span class="ref-vol">10</span>:119.</span> [<a href="/pmc/articles/PMC6367262/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6367262</span></a>] [<a href="/pubmed/30774631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30774631</span></a>]<div><i>(Review of the immunopathogenesis of the macrophage activation syndrome, a complication of several systemic inflammatory disorders including juvenile idiopathic arthritis, systemic lupus erythematosus and adult onset Still&#x02019;s disease, characterized by high circulating levels of proinflammatory cytokines which has led to the experimental use of cytokine inhibitors such as anakinra, canakinumab and rilonacept).</i></div></div></li><li><div class="bk_ref" id="Rilonacept.REF.sfriso.2020.129">Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P. Canakinumab for the treatment of adult-onset Still's disease. <span><span class="ref-journal">Expert Rev Clin Immunol. </span>2020;<span class="ref-vol">16</span>:129–38.</span> [<a href="/pubmed/31957508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31957508</span></a>]<div><i>(Review of the clinical efficacy and safety of canakinumab for adult-onset Still&#x02019;s disease for which it is not approved in the US, despite evidence for its efficacy in small case series and clinical trials; mentions that small studies of rilonacept in patients with adult-onset Still disease found it to be highly effective in alleviating symptoms and has the advantage of a longer half-life that allows weekly or every other week administration).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548482</span><span class="label">PMID: <a href="/pubmed/31643801" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643801</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Rifaximin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Rilpivirine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548482&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548482/?report=reader">PubReader</a></li><li><a href="/books/NBK548482/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548482" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548482" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Rilonacept. [Updated 2020 Apr 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548482/pdf/Bookshelf_NBK548482.pdf">PDF version of this page</a> (103K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Rilonacept+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Rilonacept: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Rilonacept" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Rilonacept: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4867600" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4867600" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22096352" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).</a><span class="source">[J Inflamm Res. 2010]</span><div class="brieflinkpop offscreen_noflow">Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gillespie J, Mathews R, McDermott MF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Inflamm Res. 2010; 3:1-8. Epub 2010 Jan 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19649332" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rilonacept in the treatment of chronic inflammatory disorders.</a><span class="source">[Drugs Today (Barc). 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rilonacept in the treatment of chronic inflammatory disorders.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">McDermott MF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs Today (Barc). 2009 Jun; 45(6):423-30. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28586272" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacological treatment options for cryopyrin-associated periodic syndromes.</a><span class="source">[Expert Rev Clin Pharmacol. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacological treatment options for cryopyrin-associated periodic syndromes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Landmann EC, Walker UA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Rev Clin Pharmacol. 2017 Aug; 10(8):855-864. Epub 2017 Jun 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19344287" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).</a><span class="source">[Expert Opin Biol Ther. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hoffman HM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Biol Ther. 2009 Apr; 9(4):519-31. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18668535" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.</a><span class="source">[Arthritis Rheum. 2008]</span><div class="brieflinkpop offscreen_noflow">Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arthritis Rheum. 2008 Aug; 58(8):2443-52. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643801" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643801" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604691d74664552c12ded145">Rilonacept - LiverTox</a><div class="ralinkpop offscreen_noflow">Rilonacept - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:06:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE890404046692E10000000008BC027D&amp;ncbi_session=CE89040404691D61_2236SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548482%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548482&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548482/&amp;ncbi_pagename=Rilonacept - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89040404691D61_2236SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>